Vepdegestrant (ARV-471): A Comprehensive Clinical and Strategic Analysis of a First-in-Class PROTAC Estrogen Receptor Degrader

I. Executive Summary

Vepdegestrant (developmental code: ARV-471) represents a paradigm shift in endocrine therapy for breast cancer, emerging as the first orally bioavailable PROteolysis TArgeting Chimera (PROTAC) protein degrader to demonstrate clinical benefit in a Phase III trial.[1] Developed by Arvinas, Inc., in collaboration with Pfizer Inc., Vepdegestrant is designed to harness the body's natural protein disposal machinery to selectively and efficiently eliminate the estrogen receptor (ER), a key driver of the most common subtype of breast cancer.[4] This report provides a comprehensive analysis of Vepdegestrant, detailing its novel mechanism of action, the full arc of its clinical development, its position within the competitive landscape, and the strategic decisions shaping its future.

The cornerstone of Vepdegestrant's clinical validation is the pivotal Phase III VERITAC-2 trial, which evaluated its efficacy and safety against the current standard-of-care selective estrogen receptor degrader (SERD), fulvestrant.[1] The trial met its primary endpoint in the prespecified population of patients with estrogen receptor-positive, human epidermal growth factor receptor 2-negative (ER+/HER2-) advanced or metastatic breast cancer harboring an activating mutation in the estrogen receptor 1 gene (

ESR1).[2] In this high-need patient group, Vepdegestrant demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS), more than doubling the median PFS from 2.1 months with fulvestrant to 5.0 months.[6]

However, consistent with a pattern observed across other novel endocrine therapies, the trial did not achieve statistical significance for its co-primary endpoint in the broader intent-to-treat (ITT) population, where the median PFS was nearly identical between the two arms.[6] This dichotomous result underscores the critical importance of biomarker selection, positioning Vepdegestrant as a precision medicine for a genomically defined subgroup of patients whose disease is driven by

ESR1 mutations.

The safety profile of Vepdegestrant has been consistently favorable and manageable across its clinical program. In the VERITAC-2 trial, most treatment-emergent adverse events (TEAEs) were low-grade, and discontinuation rates due to AEs were low.[8] A notable potential differentiator is the low incidence of severe gastrointestinal-related side effects, a common challenge with other oral endocrine therapies.[6]

Based on the strength of the VERITAC-2 data in the ESR1-mutant population, Arvinas and Pfizer submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA), which was accepted for review in August 2025.[1] The FDA has granted the application Fast Track designation and assigned a Prescription Drug User Fee Act (PDUFA) action date of June 5, 2026.[1] In a significant strategic development, the companies announced in September 2025 their decision to out-license the commercialization rights to Vepdegestrant, seeking a third-party partner to maximize its value within its targeted niche market.[12] This decision reflects a careful assessment of the evolving competitive landscape and the focused market opportunity defined by the VERITAC-2 results. Vepdegestrant's journey marks a milestone for the PROTAC platform and offers a promising new therapeutic option for a well-defined patient population with limited effective treatments.

II. Introduction: The Evolving Landscape of ER+/HER2- Breast Cancer Therapy

The Centrality of Estrogen Receptor Signaling

Breast cancer is a heterogeneous disease, but the majority of cases are driven by hormonal signaling. Approximately 70% to 75% of all breast cancers are classified as estrogen receptor-positive (ER+), meaning their growth and proliferation are dependent on the binding of estrogen to the ER.[3] This biological dependency has made the ER signaling pathway the most critical and successfully exploited therapeutic target in breast cancer for decades. The standard of care for ER+/HER2- breast cancer, particularly in the advanced or metastatic setting, is endocrine therapy (ET), which aims to disrupt this pathway.[16]

Therapeutic strategies include aromatase inhibitors (AIs), which block the production of estrogen, and agents that directly target the receptor, such as Selective Estrogen Receptor Modulators (SERMs) and Selective Estrogen Receptor Degraders (SERDs).[15] The combination of ET with cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors has become the preferred first-line treatment for advanced disease, significantly improving outcomes for many patients.[15] However, despite the initial efficacy of these regimens, nearly all patients with metastatic disease will eventually experience disease progression.

The Challenge of Acquired Endocrine Resistance

The primary obstacle in the long-term management of ER+ breast cancer is the development of acquired resistance to ET.[15] Cancer cells evolve under the selective pressure of treatment, developing mechanisms to bypass the therapeutic blockade and reactivate the ER signaling pathway. One of the most prevalent and clinically significant mechanisms of resistance is the acquisition of activating mutations in the

ESR1 gene, which encodes the ER protein.[15]

These mutations, which are rare in primary tumors, are found in up to 40-50% of patients with metastatic breast cancer whose disease has progressed on a prior AI-based therapy.[3] The mutations typically occur in the ligand-binding domain of the receptor, causing a conformational change that renders the ER constitutively active, meaning it can signal for cell growth even in the absence of its natural ligand, estrogen.[14] This estrogen-independent activity makes tumors with

ESR1 mutations resistant to AIs, which are only effective at reducing estrogen levels.[16] The presence of

ESR1 mutations is therefore a key driver of treatment failure and is associated with a poorer prognosis and shorter progression-free survival.[14]

Limitations of Existing Therapies and the Unmet Need

For patients who progress on AIs, particularly those with ESR1-mutated tumors, the therapeutic options have historically been limited. The first-in-class SERD, fulvestrant, was approved in 2002 and became a cornerstone of second-line therapy.[16] Unlike AIs, fulvestrant directly binds to the ER, inducing a conformational change that leads to its degradation, thereby removing the receptor from the cell.[19] However, fulvestrant has several significant limitations. It has poor oral bioavailability and must be administered via two large-volume, often painful, intramuscular injections on a monthly basis, which poses a considerable burden on patients.[14] Furthermore, from a pharmacological standpoint, fulvestrant achieves only partial and incomplete ER degradation in the clinical setting, with studies showing degradation levels of only 40% to 65%.[13] This incomplete target inhibition leaves a clear opportunity for the development of more potent and effective ER degraders.

These limitations established a significant and well-defined unmet medical need: the development of a potent, orally bioavailable agent capable of achieving more profound ER degradation to effectively treat patients with ER+/HER2- advanced breast cancer, especially those who have developed resistance to prior ET through mechanisms like ESR1 mutations.[1] The initial broad goal was to create a more convenient and more effective replacement for injectable fulvestrant. However, as a new generation of oral ER-targeting agents has advanced through clinical trials, this unmet need has become more refined. Clinical data from multiple programs have consistently shown that the most significant clinical benefit of these novel agents is concentrated in the patient subgroup with

ESR1 mutations.[7] This emerging evidence suggests that while the need for a better SERD is real, the most addressable clinical challenge is overcoming the specific resistance mechanism conferred by

ESR1 mutations. Consequently, the development of Vepdegestrant and its peers has increasingly focused on this precise, biomarker-defined patient population, shifting the paradigm from a broad second-line treatment to a targeted therapy for a specific genomic subtype of breast cancer.

III. Vepdegestrant: A Novel Mechanism of Targeted Protein Degradation

Vepdegestrant introduces a fundamentally new pharmacological modality to the treatment of ER+ breast cancer. It is not merely an inhibitor or a modulator but a targeted protein degrader, representing the clinical maturation of the innovative PROTAC platform.

The PROTAC Platform: Hijacking the Cell's Disposal System

PROteolysis TArgeting Chimeras (PROTACs) are engineered heterobifunctional small molecules designed to co-opt the cell’s natural protein disposal machinery, the ubiquitin-proteasome system (UPS).[4] The UPS is responsible for identifying and eliminating damaged or unnecessary proteins, maintaining cellular homeostasis. PROTACs act as a molecular bridge, featuring two distinct active domains connected by a chemical linker.[9] One domain is designed to bind to a specific protein of interest (POI)—in this case, the ER. The other domain is designed to bind to an E3 ubiquitin ligase, a key component of the UPS that "tags" proteins for destruction.[15]

By simultaneously binding both the target protein and the E3 ligase, the PROTAC brings them into close proximity, facilitating the transfer of ubiquitin molecules from the ligase to the target protein.[7] This poly-ubiquitination serves as an irreversible signal for the proteasome—the cell's protein degradation complex—to recognize and destroy the tagged protein.[24] A key feature of this mechanism is its catalytic nature; after inducing ubiquitination, the PROTAC molecule is released and can go on to engage another target protein and E3 ligase, allowing a single molecule to trigger the degradation of multiple target proteins.[13] This offers the potential for a more profound and durable pharmacodynamic effect compared to traditional inhibitors that require continuous high-level occupancy of the target's active site.

Molecular Mechanism of Action of Vepdegestrant (ARV-471)

Vepdegestrant is a potent, selective, and orally bioavailable PROTAC specifically engineered to target the ER.[1] Its molecular structure incorporates a ligand that binds with high affinity to the ligand-binding domain of the ER and a second ligand that recruits the cereblon (CRBN) E3 ubiquitin ligase.[9] By forming this ternary complex (Vepdegestrant-ER-CRBN), it directly induces the poly-ubiquitination of the ER, marking it for rapid and efficient degradation by the proteasome.[7]

The result of this process is the near-complete elimination of the ER protein from the cancer cell, which effectively shuts down the entire ER-mediated signaling axis that drives tumor growth and survival.[25] This mechanism is effective against both wild-type ER and the mutated forms of ER found in resistant tumors, as Vepdegestrant binds to a region of the receptor that is generally conserved across common

ESR1 mutations.[13] Proteomic profiling studies have confirmed the high selectivity of Vepdegestrant; when cancer cells were treated with the drug, the ESR1-encoded ER protein was the most statistically significant protein to be depleted, validating its precise, on-target mechanism of action.[24]

Pharmacological Differentiation from Conventional SERDs

The mechanism of Vepdegestrant distinguishes it fundamentally from conventional SERDs like fulvestrant, offering key pharmacological advantages.

• Direct vs. Indirect Degradation: Fulvestrant functions by binding to the ER, which induces a conformational change. This change impairs the receptor's function and immobilizes it, which in turn indirectly leads to its destabilization and eventual degradation by the cell's quality control systems.[13] In stark contrast, Vepdegestrant does not rely on indirect consequences of binding; it directly and actively recruits the UPS machinery to the ER, acting as a catalyst for a more deliberate and efficient degradation process.[7]
• Degradation Efficiency: This mechanistic difference translates into a significant disparity in degradation efficiency. As noted, fulvestrant achieves only partial ER degradation, estimated at 40-65% in clinical settings.[13] This leaves a substantial pool of residual ER protein that could potentially continue to signal or contribute to resistance. Vepdegestrant, with its more direct mechanism, has demonstrated a far superior capacity for ER elimination, achieving degradation levels of up to 97% in preclinical tumor models.[13] This more profound and near-complete removal of the target protein is the central tenet of its therapeutic hypothesis, aiming to provide a more comprehensive blockade of the ER pathway.

The core characteristics of Vepdegestrant are summarized in the table below.

Table 1: Vepdegestrant Key Characteristics

Characteristic	Description	Source(s)
Generic Name	Vepdegestrant	11
Developmental Code Name	ARV-471	9
Drug Class	PROteolysis TArgeting Chimera (PROTAC) Protein Degrader; Selective Estrogen Receptor Degrader (SERD)	25
Mechanism of Action	Simultaneously binds the Estrogen Receptor (ER) and the Cereblon (CRBN) E3 ubiquitin ligase, inducing direct ubiquitination and proteasomal degradation of the ER.	13
Target	Estrogen Receptor (ER)	4
Intended Indication	Treatment of ER-positive, HER2-negative (ER+/HER2-), ESR1-mutated advanced or metastatic breast cancer.	1
Route of Administration	Oral, once daily	3
Developers	Arvinas, Inc. and Pfizer Inc.	5

IV. Preclinical Evidence and Rationale for Clinical Development

The advancement of Vepdegestrant into a robust clinical program was underpinned by a comprehensive and compelling body of preclinical evidence that not only established its proof-of-concept but also provided a predictive blueprint for its clinical strategy. The data clearly demonstrated superiority over the existing standard of care, fulvestrant, and highlighted the specific contexts in which it was likely to be most effective.

Superior ER Degradation

The foundational preclinical data for Vepdegestrant centered on its primary pharmacological function: ER degradation. In multiple in vivo preclinical models of ER+ breast cancer, orally administered Vepdegestrant consistently demonstrated a profound level of ER degradation, reaching ≥90%.[13] This was substantially greater than the degradation achieved with fulvestrant under comparable conditions, which was measured at approximately 63-65%.[13] In some

in vitro and in vivo models, Vepdegestrant-induced ER degradation reached levels as high as 97%, indicating a near-total elimination of the target protein.[30] This superior degradation efficiency formed the core rationale for its development as a next-generation SERD.

Enhanced Anti-Tumor Efficacy

Crucially, the enhanced ER degradation observed with Vepdegestrant translated directly into superior anti-tumor activity. In orthotopic xenograft models using the MCF7 breast cancer cell line, Vepdegestrant treatment resulted in tumor growth inhibition (TGI) ranging from 87% to 123% (where values over 100% indicate tumor regression), a result that significantly outperformed the 31-80% TGI observed with fulvestrant.[13] This potent efficacy was not limited to models with wild-type ER. Vepdegestrant demonstrated robust activity in models harboring clinically relevant

ESR1 mutations, such as the Y537S mutation, which confers hormone-independent growth.[13] Furthermore, its efficacy was maintained even in models that had developed resistance to the CDK4/6 inhibitor palbociclib, suggesting that Vepdegestrant could overcome multiple mechanisms of endocrine resistance.[13]

Synergistic Combination Potential

The preclinical program also extensively explored Vepdegestrant's potential as a backbone therapy for combination regimens. Studies demonstrated strong synergistic effects when Vepdegestrant was combined with a range of standard-of-care and investigational agents. Robust tumor regressions were observed when Vepdegestrant was co-administered with all three approved CDK4/6 inhibitors (palbociclib, abemaciclib, and ribociclib).[9] Similar synergy was seen with inhibitors of the PI3K/mTOR pathway, including the mTOR inhibitor everolimus and the PI3K inhibitors alpelisib and inavolisib.[13] This broad combination potential provided a strong scientific rationale for its clinical evaluation not just as a monotherapy but also as a versatile partner for other targeted agents.

The predictive power of this preclinical data package was remarkable. The clear, head-to-head superiority in ER degradation and TGI against fulvestrant directly informed the design of the pivotal VERITAC-2 trial as a direct comparison against this standard of care. The potent activity demonstrated in ESR1 mutant models provided the confidence to designate the ESR1m population as a co-primary endpoint, correctly anticipating that the greatest effect size would be observed in this specific subgroup. Finally, the compelling evidence of synergy with CDK4/6 inhibitors laid the groundwork for the entire combination therapy development strategy, including the Phase Ib cohort with palbociclib and the subsequent design of trials like VERITAC-3 and the TACTIVE-U umbrella study. The preclinical findings were, therefore, not merely a justification for clinical testing but a detailed and accurate roadmap for the entire clinical development program.

V. Clinical Development Program

The clinical development of Vepdegestrant was systematically designed to validate the promising preclinical data, beginning with foundational safety and dose-finding studies and progressing to large-scale, pivotal trials. The program has explored Vepdegestrant both as a monotherapy and as a combination agent, reflecting its potential as a new endocrine therapy backbone.

Table 2: Summary of Major Vepdegestrant Clinical Trials

Trial ID (Phase)	NCT Number	Population	Intervention(s)	Primary Objective(s)	Status
ARV-471-mBC-101 / VERITAC (Phase I/II)	NCT04072952	Heavily pretreated ER+/HER2- advanced/metastatic BC	Vepdegestrant monotherapy; Vepdegestrant + palbociclib	Assess safety, tolerability, PK, and determine Recommended Phase 3 Dose (RP3D).	Completed
VERITAC-2 (Phase III)	NCT05654623	ER+/HER2- advanced/metastatic BC after progression on CDK4/6i + ET	Vepdegestrant vs. Fulvestrant	Progression-Free Survival (PFS) in ITT and ESR1m populations.	Active, Not Recruiting
VERITAC-3 (Phase III)	NCT05909397	First-line ER+/HER2- advanced BC	Vepdegestrant + palbociclib vs. Letrozole + palbociclib	Efficacy and safety in the first-line setting.	Terminated
TACTIVE-U (Phase Ib/II)	NCT05548127, NCT05573555	ER+/HER2- advanced/metastatic BC	Vepdegestrant + abemaciclib; Vepdegestrant + ribociclib	Safety and clinical activity of combinations.	Active, Recruiting

Phase I/II First-in-Human Study (NCT04072952)

The clinical journey for Vepdegestrant began with the ARV-471-mBC-101 study, a first-in-human Phase I/II trial designed to establish the drug's safety, tolerability, pharmacokinetic profile, and preliminary anti-tumor activity.[9] The study enrolled heavily pretreated patients with ER+/HER2- advanced or metastatic breast cancer. The dose-escalation portion of the trial successfully identified 200 mg administered orally once daily as the recommended Phase 3 dose (RP3D) for monotherapy.[15] At this dose, Vepdegestrant was well-tolerated and demonstrated durable clinical activity. Notably, in the 200 mg cohort, no patients required a dose reduction due to a treatment-emergent adverse event (TEAE), highlighting its favorable safety profile early in development.[36] The study confirmed that Vepdegestrant monotherapy had clinical activity in this pretreated patient population, providing the necessary validation to proceed to Phase III investigation.[15]

Combination with Palbociclib (Phase Ib cohort of NCT04072952)

Building on the strong preclinical synergy data, a Phase Ib cohort of the same study evaluated Vepdegestrant in combination with the CDK4/6 inhibitor palbociclib.[25] This cohort enrolled 46 heavily pretreated patients who had received a median of four prior lines of therapy, with 87% having had prior CDK4/6 inhibitor treatment.[38] The combination demonstrated encouraging and durable clinical activity:

• Clinical Benefit Rate (CBR): The CBR, defined as a complete response, partial response, or stable disease for at least 24 weeks, was 63% in the overall population. The benefit was even more pronounced in patients with known ESR1 mutations, where the CBR reached 72%.[25]
• Objective Response Rate (ORR): In patients with measurable disease, the combination achieved an ORR of 42%.[25]
• Median Progression-Free Survival (mPFS): The mPFS was 11.2 months for the overall cohort. In the subset of patients treated at the 200 mg RP3D of Vepdegestrant, the mPFS was 13.9 months, a highly promising signal in such a heavily pretreated population.[38]

The safety profile of the combination was manageable and consistent with the known individual profiles of Vepdegestrant and palbociclib, with no new safety signals emerging.[38] These positive results provided a strong rationale for exploring the combination in earlier lines of therapy, which was the basis for the now-terminated VERITAC-3 trial.[33]

Other Investigational Combinations

The potential of Vepdegestrant as a versatile endocrine therapy backbone is being further explored in the TACTIVE-U umbrella study.[41] This Phase Ib/II trial is designed to evaluate the safety and clinical activity of Vepdegestrant in combination with the other two approved CDK4/6 inhibitors, abemaciclib and ribociclib.[25] Preclinical data also support potential combinations with other agents such as the mTOR inhibitor everolimus and the investigational CDK4 inhibitor samuraciclib, indicating a broad and ongoing effort to define the optimal therapeutic context for Vepdegestrant beyond its use as a monotherapy.[2]

VI. The VERITAC-2 Phase III Trial: A Pivotal Head-to-Head Evaluation

The VERITAC-2 trial represents the definitive clinical assessment of Vepdegestrant monotherapy, providing the pivotal data for regulatory submission. Its design and results have been instrumental in defining the drug's specific role in the treatment of ER+/HER2- advanced breast cancer.

Trial Design and Methodology (NCT05654623)

VERITAC-2 was a global, randomized, open-label Phase III trial designed to directly compare the efficacy and safety of Vepdegestrant against the established SERD, fulvestrant.[1] The study enrolled 624 patients with ER+/HER2- advanced or metastatic breast cancer whose disease had progressed following treatment with a first-line regimen of a CDK4/6 inhibitor plus an endocrine therapy.[4] This "second-line plus" setting represents a critical juncture in patient care where treatment options are limited and resistance is common.

Patients were randomized in a 1:1 ratio to one of two arms [8]:

1. Vepdegestrant Arm: 200 mg administered orally once daily on a continuous schedule.
2. Fulvestrant Arm: 500 mg administered intramuscularly on Days 1 and 15 of the first cycle, and then on Day 1 of each subsequent 28-day cycle.

The trial design incorporated key stratification factors, including the presence or absence of an ESR1 mutation (detected in circulating tumor DNA) and the presence of visceral (organ) metastases.[8] The study featured co-primary endpoints of progression-free survival (PFS), as determined by a blinded independent central review (BICR), assessed in two distinct populations: the overall intent-to-treat (ITT) population (all 624 patients) and the subgroup of patients with detectable

ESR1 mutations (ESR1m).[3]

Efficacy in the ESR1-Mutant Population: A Clear Success

In the prespecified ESR1m population, which comprised 270 patients (43.3% of the total), the VERITAC-2 trial met its primary endpoint with a high degree of statistical and clinical significance.[2] The results demonstrated a clear superiority of Vepdegestrant over fulvestrant in this biomarker-defined subgroup.

• Progression-Free Survival (PFS): Vepdegestrant more than doubled the median PFS compared to fulvestrant, achieving a median of 5.0 months versus 2.1 months for the fulvestrant arm.[6] This outcome represented a 43% reduction in the risk of disease progression or death, as indicated by a Hazard Ratio (HR) of 0.57 (95% Confidence Interval [CI] 0.42–0.77; p=0.0001).[6] The PFS benefit was consistent across key subgroups, with 6-month PFS rates of 45.2% for Vepdegestrant compared to just 22.7% for fulvestrant.[26]
• Objective Response Rate (ORR): The rate of tumor shrinkage was substantially higher with Vepdegestrant. The ORR was 18.6% in the Vepdegestrant arm, more than four times higher than the 4.0% observed in the fulvestrant arm (Odds Ratio = 5.45; nominal p=0.001).[6]
• Clinical Benefit Rate (CBR): Similarly, the CBR, which includes patients with stable disease for at least 24 weeks, was more than doubled with Vepdegestrant, at 42.1% versus 20.2% for fulvestrant (OR = 2.88; nominal p<0.001).[6]

Analysis of the Intent-to-Treat (ITT) Population: Failure to Reach Significance

In contrast to the robust benefit seen in the ESR1m subgroup, Vepdegestrant did not demonstrate a statistically significant improvement in PFS in the overall ITT population.[2] The median PFS was nearly indistinguishable between the two treatment arms:

3.7 months for Vepdegestrant versus 3.6 months for fulvestrant.[6] The hazard ratio was 0.83 (95% CI 0.68–1.02), and the result did not meet the prespecified threshold for statistical significance (p=0.07).[6]

Secondary Endpoints

At the time of the primary data analysis, the key secondary endpoint of Overall Survival (OS) was immature, with fewer than a quarter of the required number of events having occurred.[3] The trial will continue to follow patients to assess long-term survival outcomes.

Table 3: Pivotal Efficacy Results of the VERITAC-2 Trial

Endpoint	Patient Population	Vepdegestrant Arm	Fulvestrant Arm	Hazard/Odds Ratio (95% CI)	p-value
Median PFS (by BICR)	ESR1-Mutant (n=270)	5.0 months	2.1 months	HR = 0.57 (0.42–0.77)	0.0001
Median PFS (by BICR)	Intent-to-Treat (n=624)	3.7 months	3.6 months	HR = 0.83 (0.68–1.02)	0.07 (ns)
Objective Response Rate (ORR)	ESR1-Mutant	18.6%	4.0%	OR = 5.45 (1.69–22.73)	0.001 (nominal)
Clinical Benefit Rate (CBR)	ESR1-Mutant	42.1%	20.2%	OR = 2.88 (1.57–5.39)	<0.001 (nominal)
Data sourced from.6 ns = not significant.

The results from VERITAC-2 are highly significant, not just for Vepdegestrant but for the entire class of next-generation ER-targeting therapies. The trial's outcome provides a powerful confirmation of a pattern first observed in the EMERALD trial of elacestrant and hinted at in the acelERA trial of giredestrant: the primary clinical benefit of these potent oral SERDs is concentrated in the patient population where the ESR1 mutation is the dominant, targetable driver of resistance.[7] The initial broad hypothesis of replacing fulvestrant for all post-AI patients has been definitively refined by this collective clinical evidence. The failure to show a benefit in the ITT population is not a failure of the drug's mechanism but rather a crucial finding that validates the necessity of a precision medicine strategy. This outcome solidifies the clinical practice of using biomarker testing—specifically, screening for

ESR1 mutations via circulating tumor DNA upon progression—to identify the patients most likely to benefit from this class of therapies. It is this clear, biomarker-defined efficacy that formed the basis of the targeted NDA submission to the FDA.

VII. Comprehensive Safety and Tolerability Assessment

A critical component of any new cancer therapy, particularly in the metastatic setting where quality of life is paramount, is its safety and tolerability profile. Across its clinical development program, Vepdegestrant has consistently demonstrated a favorable safety profile that is manageable for patients undergoing long-term treatment.

Overall Profile

The safety of Vepdegestrant has been evaluated as a monotherapy and in combination with other agents, with the pivotal VERITAC-2 trial providing the most robust dataset for its use as a single agent.[2] In this trial, Vepdegestrant was generally well-tolerated, and its safety profile was consistent with observations from earlier-phase studies, with no new or unexpected safety signals emerging.[3]

Adverse Events in VERITAC-2

The majority of treatment-emergent adverse events (TEAEs) reported in the Vepdegestrant arm of the VERITAC-2 trial were of low severity (Grade 1 or 2).[6]

• Incidence of Severe Events: Grade 3 or higher TEAEs occurred in 23.4% of patients receiving Vepdegestrant, compared to 17.6% of patients receiving fulvestrant.[8] Serious adverse events were reported in 10% of patients on Vepdegestrant and 9% on fulvestrant.[45] Grade 4 TEAEs were infrequent, occurring in only 1.6% of patients in the Vepdegestrant arm versus 2.9% in the fulvestrant arm.[6]
• Common Adverse Events: The most frequently reported any-grade TEAEs in patients treated with Vepdegestrant were fatigue (26.6%), increased alanine transaminase (ALT) (14.4%), increased aspartate aminotransferase (AST) (14.4%), and nausea (13.5%).[6]
• Gastrointestinal Tolerability: A key aspect of Vepdegestrant's safety profile is its gastrointestinal (GI) tolerability. The rates of GI-related adverse events were notably low, with any-grade nausea reported in 13.5% of patients, vomiting in 6.4%, and diarrhea in 6.4%.[6] The low incidence of these often burdensome side effects may represent a significant quality-of-life advantage and a point of differentiation from other oral endocrine therapies.
• Specific Grade ≥3 Events: The most common Grade 3-4 adverse events attributed to Vepdegestrant were hematological, including neutropenia (1.9%), and metabolic, such as hypokalemia (1.9%).[47]

Discontinuation Rates

The overall tolerability of a drug is often best reflected by the rate at which patients must discontinue treatment due to side effects. For Vepdegestrant, this rate was very low. In the VERITAC-2 trial, only 2.9% of patients permanently discontinued Vepdegestrant due to a TEAE, compared to 0.7% in the fulvestrant arm.[8] This low discontinuation rate, despite a slightly higher incidence of Grade ≥3 AEs compared to fulvestrant, supports the conclusion that the adverse events associated with Vepdegestrant are generally manageable in the clinical setting.

Table 4: Comparative Safety Profile from the VERITAC-2 Trial

Adverse Event	Vepdegestrant (n=312) - Any Grade (%)	Vepdegestrant (n=312) - Grade ≥3 (%)	Fulvestrant (n=307) - Any Grade (%)	Fulvestrant (n=307) - Grade ≥3 (%)
Any TEAE	87%	23.4%	81%	17.6%
Serious AEs	10%	N/A	9%	N/A
TEAE Leading to Discontinuation	2.9%	N/A	0.7%	N/A
Fatigue	26.6%	<5%	15.6%	<5%
Nausea	13.5%	<5%	8.8%	<5%
Vomiting	6.4%	<5%	N/A	N/A
Diarrhea	6.4%	<5%	N/A	N/A
ALT Increased	14.4%	<5%	9.8%	<5%
AST Increased	14.4%	<5%	10.4%	<5%
Neutropenia	12%	1.9%	5%	N/A
Anemia	12%	<5%	8%	<5%
Data compiled from.6 N/A indicates data not specified in the provided sources.

VIII. Regulatory and Commercial Trajectory

The path of Vepdegestrant from clinical trial success to potential market availability has been shaped by a clear regulatory strategy in the United States and a significant, more recent pivot in its commercialization plan.

Regulatory Pathway in the United States

The development of Vepdegestrant has been facilitated by a supportive regulatory environment, acknowledging the need for new treatments in this disease setting.

• Fast Track Designation: Early in its development, Vepdegestrant received Fast Track Designation from the U.S. FDA.[3] This designation is intended to facilitate the development and expedite the review of drugs that treat serious conditions and fill an unmet medical need.[25] It signals the FDA's recognition of the potential for Vepdegestrant to provide a meaningful new option for patients with ER+/HER2- metastatic breast cancer who have progressed on prior endocrine-based therapies.[4]
• New Drug Application (NDA) Submission and Acceptance: Following the positive topline results from the VERITAC-2 trial, Arvinas and Pfizer submitted a New Drug Application (NDA) to the FDA on June 6, 2025.[11] The FDA formally accepted the NDA for review on August 8, 2025.[1] The application is based on the strength of the data from the ESR1m population in the VERITAC-2 trial.
• PDUFA Date: With the acceptance of the NDA, the FDA has assigned a Prescription Drug User Fee Act (PDUFA) action date of June 5, 2026.[1] This is the target date by which the agency aims to complete its review and make a decision regarding the approval of Vepdegestrant.
• Proposed Indication: The NDA specifically seeks approval for Vepdegestrant as a monotherapy for the treatment of adult patients with ER+/HER2-, ESR1-mutated advanced or metastatic breast cancer who have previously been treated with endocrine-based therapy.[1] This targeted indication directly reflects the clinical trial results, where the benefit was clearly demonstrated in this biomarker-defined population.

Status in Europe and Other Regions

As of late 2025, a review of the European Medicines Agency (EMA) public databases indicates that a marketing authorisation application for Vepdegestrant has not yet been submitted or approved.[49] However, the global nature of the VERITAC-2 trial, which included sites in 25 countries, and the presence of ongoing earlier-phase studies in Europe, such as a Phase Ib/II combination trial in Belgium, France, and Spain, suggest that data are being generated to potentially support future regulatory filings in the EU and other regions.[1]

Strategic Repositioning: The Out-Licensing Decision

In a major strategic shift announced on September 17, 2025, Arvinas and Pfizer jointly agreed to out-license the commercialization rights for Vepdegestrant.[12] Rather than pursuing commercialization themselves, the two companies have begun a formal process to seek a third-party partner with the established capabilities and expertise in oncology to handle the potential launch and marketing of the drug, if approved.[12]

This decision was a direct consequence of the VERITAC-2 trial results and a subsequent reassessment of the drug's market potential. The failure to show a benefit in the broader ITT population, coupled with the prior cancellation of planned Phase III trials that would have explored Vepdegestrant in larger, earlier-line settings, effectively narrowed the immediate commercial opportunity to the second-line, ESR1-mutant niche.[40] This focused market, while representing a significant unmet need, may not align with the large-scale commercial infrastructure and revenue expectations of a major pharmaceutical company like Pfizer, nor does it justify the expense of Arvinas building its own commercial team from scratch.[54]

The implication of this move is a pragmatic recognition that the value of Vepdegestrant can be best maximized by a company with an existing, synergistic oncology portfolio that can efficiently launch and support a targeted, biomarker-driven therapy.[12] For Arvinas, this decision allows the company to monetize the asset and refocus its resources and capital on its earlier-stage pipeline of PROTAC degraders, leading to significant cost savings and workforce reductions primarily affecting roles planned for Vepdegestrant commercialization.[12]

IX. Competitive Landscape and Future Perspectives

Vepdegestrant is poised to enter a dynamic and increasingly competitive therapeutic landscape for ER+/HER2- breast cancer. Its clinical and commercial potential must be assessed relative to the existing standard of care, the first-to-market oral competitor, and other novel agents in late-stage development.

Table 5: Competitive Landscape of Oral ER-Targeting Therapies in ER+/HER2- Breast Cancer

Drug Name (Brand)	Company	Mechanism	Route of Admin	Regulatory Status	Key Phase III Efficacy (PFS in ESR1m vs. SOC)
Vepdegestrant	Arvinas/Pfizer	PROTAC ER Degrader	Oral	NDA Accepted (US)	mPFS 5.0 mo vs 2.1 mo (fulvestrant); HR=0.57 (VERITAC-2)
Fulvestrant (Faslodex)	AstraZeneca	SERD	IM Injection	Approved	Standard of Care (Comparator)
Elacestrant (Orserdu)	Menarini/Stemline	SERD	Oral	Approved (US/EU)	mPFS 3.8 mo vs 1.9 mo (SOC); HR=0.55 (EMERALD)
Camizestrant	AstraZeneca	SERD	Oral	Investigational	mPFS 16.0 mo vs 9.2 mo (AI) in 1L ESR1 emergence setting; HR=0.44 (SERENA-6)
Giredestrant	Roche/Genentech	SERD	Oral	Investigational	mPFS 5.3 mo vs 3.5 mo (SOC); No significant difference (acelERA)
Data sourced from.6

Comparative Analysis

• vs. Fulvestrant: Vepdegestrant holds two clear and significant advantages over the long-standing standard of care, fulvestrant. The first is the convenience of once-daily oral administration compared to painful monthly intramuscular injections, a factor that heavily influences patient preference.[14] The second is the superior efficacy demonstrated in the VERITAC-2 trial for the ESR1-mutant population, where Vepdegestrant more than doubled the median PFS.[6]
• vs. Elacestrant (Orserdu): Elacestrant is Vepdegestrant's most direct competitor, being the first oral SERD approved by the FDA and EMA for the same indication: second-line treatment of ER+/HER2- advanced breast cancer with an ESR1 mutation.[16] A cross-trial comparison of the pivotal data suggests Vepdegestrant may have a slight efficacy edge, with the VERITAC-2 trial reporting a median PFS of 5.0 months (HR=0.57) compared to 3.8 months (HR=0.55) for elacestrant in the EMERALD trial.[6] However, the primary point of differentiation may lie in the safety and tolerability profile. Vepdegestrant has shown low rates of GI toxicity [6], whereas nausea is a very common adverse event with elacestrant, reported in 35% of patients in its pivotal trial.[62] A more favorable tolerability profile could be a key factor for physician and patient choice in a market with multiple options.
• vs. Other Investigational Agents: The competitive field includes other oral SERDs in late-stage development. AstraZeneca's camizestrant has produced highly impressive results in the SERENA-6 trial, showing a median PFS of 16.0 months (HR=0.44) when used to replace an AI upon the first detection of an ESR1 mutation in the first-line setting.[60] While this is a different clinical scenario than the one studied in VERITAC-2, it positions camizestrant as a formidable future competitor. Conversely, Roche's giredestrant failed to demonstrate a statistically significant PFS benefit in its Phase II acelERA trial, potentially hindering its competitive standing.[27]

Future Clinical Directions

While the immediate path to market for Vepdegestrant is as a monotherapy in the second-line ESR1-mutant setting, its long-term potential may be realized in combination therapies. The strong preclinical data and the promising Phase Ib results with palbociclib suggest that Vepdegestrant could serve as a highly effective endocrine backbone for combination with CDK4/6 inhibitors or other targeted agents.[24] The pursuit of these broader indications, particularly in earlier lines of therapy, would require substantial investment in new, large-scale clinical trials. The decision to out-license the drug means that its future development path will be determined by the strategic priorities and resources of its eventual commercial partner.[57] The unique PROTAC mechanism may also offer opportunities to overcome resistance pathways that are not adequately addressed by conventional SERDs, a hypothesis that warrants further clinical exploration.

Concluding Assessment

Vepdegestrant represents a significant scientific and clinical achievement. It is the first PROTAC degrader to successfully complete a Phase III trial and demonstrate a clear clinical benefit, validating this novel therapeutic modality in oncology.[1] Its clinical profile is defined by robust efficacy in the biomarker-selected

ESR1-mutant patient population and a favorable tolerability profile. While its market opportunity has been focused by the VERITAC-2 results, it is well-positioned to be a potential best-in-class treatment option within this important clinical niche. The ultimate success of Vepdegestrant now hinges on the strategic execution of its future partner, who will be tasked with navigating a competitive landscape, securing regulatory approvals, and ensuring that this innovative therapy reaches the patients who stand to benefit most.

X. Conclusion

Vepdegestrant (ARV-471) has successfully navigated the path from a novel scientific concept to a clinically validated therapeutic agent, marking a pivotal moment for the field of targeted protein degradation. As the first PROTAC to demonstrate efficacy in a Phase III trial, it has provided crucial validation for a new class of medicines designed to eliminate disease-causing proteins rather than simply inhibiting them.

The clinical development program, culminating in the VERITAC-2 trial, has precisely defined Vepdegestrant's role in the management of ER+/HER2- advanced breast cancer. The data unequivocally support its use as a highly effective monotherapy for patients whose disease is characterized by ESR1 mutations, a common and challenging mechanism of acquired resistance to standard endocrine therapies. In this population, Vepdegestrant offers a clinically meaningful improvement in progression-free survival over the current injectable standard of care, fulvestrant. This efficacy is complemented by a favorable safety profile and the significant quality-of-life advantage of an oral, once-daily administration.

The failure to demonstrate a benefit in the broader all-comers population is not a setback but rather a critical scientific finding that reinforces the imperative of a precision medicine approach in modern oncology. Vepdegestrant's story, alongside that of its oral SERD peers, confirms that the future of endocrine therapy lies in the molecular characterization of tumors and the selection of therapies based on specific resistance mechanisms.

The strategic decision by Arvinas and Pfizer to out-license Vepdegestrant reflects a pragmatic assessment of a focused market opportunity. While Vepdegestrant is poised to be a potential best-in-class agent, its success will be realized within a specific, biomarker-defined niche. For patients with ESR1-mutant, ER+/HER2- advanced breast cancer, Vepdegestrant represents a significant and welcome therapeutic advancement. Its journey from laboratory to late-stage regulatory review is a testament to the power of innovative drug design and rigorous clinical investigation. Pending regulatory approval and the successful engagement of a commercial partner, Vepdegestrant is set to become an important new tool for oncologists and a new source of hope for patients facing this difficult disease.

Works cited

1. Arvinas Announces FDA Acceptance of the New Drug Application for Vepdegestrant for the Treatment of ESR1m, ER+/HER2- Advanced Breast Cancer, accessed September 19, 2025, https://ir.arvinas.com/news-releases/news-release-details/arvinas-announces-fda-acceptance-new-drug-application/
2. VERITAC-2 Trial Shows Vepdegestrant Significantly Improves ..., accessed September 19, 2025, https://www.appliedclinicaltrialsonline.com/view/veritac-trial-vepdegestrant-survival-esr1-mutant-breast-cancer
3. Arvinas and Pfizer Announce Positive Topline Results from Phase 3 VERITAC-2 Clinical Trial, accessed September 19, 2025, https://ir.arvinas.com/news-releases/news-release-details/arvinas-and-pfizer-announce-positive-topline-results-phase-3/
4. Arvinas Announces Submission of New Drug Application to U.S. FDA for Vepdegestrant for Patients with ESR1-Mutated ER+/HER2- Advanced or Metastatic Breast Cancer, accessed September 19, 2025, https://ir.arvinas.com/news-releases/news-release-details/arvinas-announces-submission-new-drug-application-us-fda/
5. Arvinas and Pfizer Announce Positive Topline Results from Phase 3 VERITAC-2 Clinical Trial, accessed September 19, 2025, https://www.pfizer.com/news/press-release/press-release-detail/arvinas-and-pfizer-announce-positive-topline-results-phase
6. Arvinas and Pfizer's Vepdegestrant Significantly Improves Progression-Free Survival for Patients with ESR1-Mutant, ER+/HER2- Advanced Breast Cancer, accessed September 19, 2025, https://www.pfizer.com/news/press-release/press-release-detail/arvinas-and-pfizers-vepdegestrant-significantly-improves
7. VERITAC-2: Vepdegestrant Delivers Significantly Longer PFS Than Fulvestrant in ESR1-Mutated, ER-Positive/HER2-Negative Advanced Breast Cancer - ASCO Daily News, accessed September 19, 2025, https://dailynews.ascopubs.org/do/veritac-2-vepdegestrant-delivers-significantly-longer-pfs-than-fulvestrant-esr1-
8. Vepdegestrant, a PROTAC estrogen receptor (ER) degrader, vs fulvestrant in ER-positive/human epidermal growth factor receptor 2 (HER2)–negative advanced breast cancer: Results of the global, randomized, phase 3 VERITAC-2 study. - ASCO, accessed September 19, 2025, https://www.asco.org/abstracts-presentations/ABSTRACT483122
9. Vepdegestrant - Wikipedia, accessed September 19, 2025, https://en.wikipedia.org/wiki/Vepdegestrant
10. Vepdegestrant Improves PFS in Select Patients With ESR1-Mutant Advanced Breast Cancer, accessed September 19, 2025, https://ascopost.com/news/may-2025/vepdegestrant-improves-pfs-in-select-patients-with-esr1-mutant-advanced-breast-cancer
11. Vepdegestrant: What is it and is it FDA approved? - Drugs.com, accessed September 19, 2025, https://www.drugs.com/history/vepdegestrant.html
12. Arvinas Provides Update on Collaboration with Pfizer and Announces Further Actions to Support Value Creation, accessed September 19, 2025, https://ir.arvinas.com/news-releases/news-release-details/arvinas-provides-update-collaboration-pfizer-and-announces/
13. Oral Estrogen Receptor PROTAC Vepdegestrant (ARV-471) Is Highly Efficacious as Monotherapy and in Combination with CDK4/6 or PI3K/mTOR Pathway Inhibitors in Preclinical ER+ Breast Cancer Models - PMC - PubMed Central, accessed September 19, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC11325148/
14. The Promise of Oral SERDs for ER+, HER2- Metastatic Breast Cancer - Eli Lilly, accessed September 19, 2025, https://www.lilly.com/news/stories/promise-of-oral-serds-mbc
15. VERITAC-2: a Phase III study of vepdegestrant, a PROTAC ER degrader, versus fulvestrant in ER+/HER2- advanced breast cancer - PubMed Central, accessed September 19, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC11524203/
16. Novel oral selective estrogen receptor degraders (SERDs) to target hormone receptor positive breast cancer: elacestrant as the poster-child - PubMed, accessed September 19, 2025, https://pubmed.ncbi.nlm.nih.gov/38642015/
17. Full article: EMERALD: Phase III Trial of Elacestrant (RAD1901) vs Endocrine Therapy for Previously Treated ER+ Advanced Breast Cancer - Taylor & Francis Online, accessed September 19, 2025, https://www.tandfonline.com/doi/full/10.2217/fon-2019-0370
18. Oral SERD, a Novel Endocrine Therapy for Estrogen Receptor-Positive Breast Cancer, accessed September 19, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC10854647/
19. en.wikipedia.org, accessed September 19, 2025, https://en.wikipedia.org/wiki/Fulvestrant#:~:text=Fulvestrant%20is%20a%20selective%20estrogen,the%20United%20States%20in%202002.
20. Fulvestrant - Wikipedia, accessed September 19, 2025, https://en.wikipedia.org/wiki/Fulvestrant
21. The history and mechanism of action of fulvestrant - PubMed, accessed September 19, 2025, https://pubmed.ncbi.nlm.nih.gov/15865849/
22. The History and Mechanism of Action of Fulvestrant | Request PDF - ResearchGate, accessed September 19, 2025, https://www.researchgate.net/publication/7872064_The_History_and_Mechanism_of_Action_of_Fulvestrant
23. Update on Oral SERDs for Estrogen Receptor-Positive MBC - Metastatic Trial Talk, accessed September 19, 2025, https://metastatictrialtalk.org/research-news/oral-serds/
24. Oral Estrogen Receptor PROTAC Vepdegestrant (ARV-471) Is Highly Efficacious as Monotherapy and in Combination with CDK4/6 or PI3K/mTOR Pathway Inhibitors in Preclinical ER+ Breast Cancer Models - AACR Journals, accessed September 19, 2025, https://aacrjournals.org/clincancerres/article/30/16/3549/746781/Oral-Estrogen-Receptor-PROTAC-Vepdegestrant-ARV
25. Vepdegestrant (ARV-471): FDA Fast Track Designation in ER+/HER2- Metastatic Breast Cancer - CancerConnect, accessed September 19, 2025, https://news.cancerconnect.com/vepdegestrant-arv-471-fda-fast-track-designation-in-er-her2-metastatic-breast-cancer/
26. FDA Accepts NDA for Vepdegestrant in ER+/HER2- Metastatic Breast Cancer, accessed September 19, 2025, https://www.targetedonc.com/view/fda-accepts-nda-for-vepdegestrant-in-er-her2--metastatic-breast-cancer
27. A trial looking at a giredestrant for breast cancer (acelERA Breast ..., accessed September 19, 2025, https://www.cancerresearchuk.org/about-cancer/find-a-clinical-trial/a-trial-looking-at-a-giredestrant-for-breast-cancer-acelera-breast-cancer
28. NDA Submission of Vepdegestrant (ARV-471) to U.S. FDA: The Beginning of a New Era of PROTAC Degraders | Journal of Medicinal Chemistry - ACS Publications, accessed September 19, 2025, https://pubs.acs.org/doi/10.1021/acs.jmedchem.5c01818
29. pmc.ncbi.nlm.nih.gov, accessed September 19, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC11524203/#:~:text=Vepdegestrant%20is%20a%20small%2Dmolecule,changes%20in%20ER%20that%20may
30. Estrogen Receptor | Arvinas, accessed September 19, 2025, https://www.arvinas.com/research-and-development/estrogen-receptor/
31. VERITAC-2: a Phase III study of vepdegestrant, a PROTAC ER degrader, versus fulvestrant in ER+/HER2- advanced breast cancer - PubMed, accessed September 19, 2025, https://pubmed.ncbi.nlm.nih.gov/39072356/
32. vepdegestrant (Pending FDA Approval) - Medscape Reference, accessed September 19, 2025, https://reference.medscape.com/drug/vepdegestrant-4000562
33. FDA Grants Fast Track Status to Vepdegestrant for ER+/HER2– Metastatic Breast Cancer, accessed September 19, 2025, https://www.onclive.com/view/fda-grants-fast-track-status-to-vepdegestrant-for-er-her2-metastatic-breast-cancer
34. reference.medscape.com, accessed September 19, 2025, https://reference.medscape.com/drug/vepdegestrant-4000562#:~:text=Brand%20and%20Other%20Names%3A,Classes%3A%20Selective%20Estrogen%20Receptor%20Degraders
35. Vepdegestrant ARV-471 - Arvinas Medical Affairs, accessed September 19, 2025, https://arvinasmedical.com/development-program/vepdegestrant-arv-471-2/
36. Safety and pharmacokinetics of vepdegestrant in Japanese patients with ER+ advanced breast cancer: a phase 1 study - PubMed Central, accessed September 19, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC11700046/
37. Vepdegestrant, a PROTAC estrogen receptor (ER) degrader, vs fulvestrant in ER-positive/human epidermal growth factor receptor 2 (HER2)–negative advanced breast cancer: Results of the global, randomized, phase 3 VERITAC-2 study. - ASCO Publications, accessed September 19, 2025, https://ascopubs.org/doi/10.1200/JCO.2025.43.17_suppl.LBA1000
38. Arvinas and Pfizer Announce Updated Clinical Data from Phase 1b Trial of Vepdegestrant in Combination with Palbociclib (IBRANCE®), accessed September 19, 2025, https://www.pfizer.com/news/press-release/press-release-detail/arvinas-and-pfizer-announce-updated-clinical-data-phase-1b
39. Vepdegestrant Plus Palbociclib Sustains Efficacy in Advanced ER+ Breast Cancer | OncLive, accessed September 19, 2025, https://www.onclive.com/view/vepdegestrant-plus-palbociclib-sustains-efficacy-in-advanced-er-breast-cancer
40. Pfizer, Arvinas lose interest in commercializing PROTAC drug - Fierce Biotech, accessed September 19, 2025, https://www.fiercebiotech.com/biotech/pfizer-arvinas-lose-interest-commercializing-protac-inhibitor-leading-layoffs-biotech
41. TACTIVE-U: Phase 1b/2 umbrella study of ARV-471, a proteolysis targeting chimera (PROTAC) estrogen receptor (ER) degrader, combined with other anticancer treatments in ER+ advanced or metastatic breast cancer. - ASCO Publications, accessed September 19, 2025, https://ascopubs.org/doi/10.1200/JCO.2023.41.16_suppl.TPS1121
42. Study Details | NCT05501769 | ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer | ClinicalTrials.gov, accessed September 19, 2025, https://clinicaltrials.gov/study/NCT05501769
43. Phase III Trial Data Show Vepdegestrant Produces Encouraging Outcomes in ER+/HER2- Advanced or Metastatic Breast Cancer - Pharmaceutical Executive, accessed September 19, 2025, https://www.pharmexec.com/view/phase-iii-trial-data-vepdegestrant-produces-encouraging-outcomes-er-her2-advanced-metastatic-breast-cancer
44. Vepdegestrant (ARV-471) - Clinical Trial Details | Pfizer Oncology Development Website, accessed September 19, 2025, https://www.pfizeroncologydevelopment.com/clinical_trial/NCT05654623/molecule/792
45. Vepdegestrant Improves PFS in ESR1-Mutant ER+/HER2– Advanced Breast Cancer, accessed September 19, 2025, https://www.onclive.com/view/vepdegestrant-improves-pfs-in-esr1-mutant-er-her2-advanced-breast-cancer
46. Vepdegestrant Meets PFS Primary End Point in ESR1m ER+/HER2– Breast Cancer, accessed September 19, 2025, https://www.cancernetwork.com/view/vepdegestrant-meets-pfs-primary-end-point-in-esr1m-er-her2-breast-cancer
47. Vepdegestrant extends progression-free survival in ER-positive, HER2-negative breast cancer | 2 Minute Medicine, accessed September 19, 2025, https://www.2minutemedicine.com/vepdegestrant-extends-progression-free-survival-in-er-positive-her2-negative-breast-cancer/
48. Press Releases - Arvinas Investor Relations, accessed September 19, 2025, https://ir.arvinas.com/press-releases/
49. Orserdu | European Medicines Agency (EMA), accessed September 19, 2025, https://www.ema.europa.eu/en/medicines/human/EPAR/orserdu
50. Truqap | European Medicines Agency (EMA), accessed September 19, 2025, https://www.ema.europa.eu/en/medicines/human/EPAR/truqap
51. European Medicines Agency (EMA), accessed September 19, 2025, https://www.ema.europa.eu/en/medicines
52. Authorisation of medicines | European Medicines Agency (EMA) - European Union, accessed September 19, 2025, https://www.ema.europa.eu/en/about-us/what-we-do/authorisation-medicines
53. Clinical Trials in the European Union - EMA, accessed September 19, 2025, https://euclinicaltrials.eu/ctis-public/view/2023-508130-33-00
54. Arvinas rules out a solo vepdegestrant launch | ApexOnco - Oncology Pipeline, accessed September 19, 2025, https://www.oncologypipeline.com/apexonco/arvinas-rules-out-solo-vepdegestrant-launch
55. Arvinas Provides Update on Collaboration with Pfizer and Announces Further Actions to Support Value Creation - GlobeNewswire, accessed September 19, 2025, https://www.globenewswire.com/news-release/2025/09/17/3152028/0/en/Arvinas-Provides-Update-on-Collaboration-with-Pfizer-and-Announces-Further-Actions-to-Support-Value-Creation.html
56. Vepdegestrant Up For Grabs As Pfizer And Arvinas Step Aside - Citeline News & Insights, accessed September 19, 2025, https://insights.citeline.com/scrip/business/strategy/vepdegestrant-up-for-grabs-as-pfizer-and-arvinas-step-aside-V7KR4AUVUZDN3MIBQ7XYPJMQ3Q/
57. Neither Arvinas nor Pfizer now wants vepdegestrant | ApexOnco - Oncology Pipeline, accessed September 19, 2025, https://www.oncologypipeline.com/apexonco/neither-arvinas-nor-pfizer-now-wants-vepdegestrant
58. Arvinas to Cut 15% of Staff Amid Vepdegestrant Outsourcing - Morningstar, accessed September 19, 2025, https://www.morningstar.com/news/dow-jones/202509178582/arvinas-to-cut-15-of-staff-amid-vepdegestrant-outsourcing
59. Elacestrant in ER + , HER2 − Metastatic Breast Cancer with ESR1-Mutated Tumors: Subgroup Analyses from the Phase III EMERALD Trial by Prior Duration of Endocrine Therapy plus CDK4/6 Inhibitor and in Clinical Subgroups - AACR Journals, accessed September 19, 2025, https://aacrjournals.org/clincancerres/article/30/19/4299/748559/Elacestrant-in-ER-HER2-Metastatic-Breast-Cancer
60. Camizestrant reduced the risk of disease progression or death by 56 ..., accessed September 19, 2025, https://www.astrazeneca.com/media-centre/press-releases/2025/camizestrant-reduced-the-risk-of-disease-progression-or-death-by-56-in-patients-with-advanced-hr-positive-breast-cancer-with-an-emergent-esr1-tumour-mutation-in-serena-6-phase-iii-trial.html
61. Giredestrant for Estrogen Receptor–Positive, HER2-Negative, Previously Treated Advanced Breast Cancer: Results From the Randomized, Phase II acelERA Breast Cancer Study - ASCO Publications, accessed September 19, 2025, https://ascopubs.org/doi/10.1200/JCO.23.01500
62. Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial - ASCO Publications, accessed September 19, 2025, https://ascopubs.org/doi/10.1200/JCO.22.00338
63. This label may not be the latest approved by FDA. For current ..., accessed September 19, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/217639Orig1s001lbl.pdf
64. ESR1-Mutated ER+/HER2 mBC Treatment - ORSERDU® (elacestrant), accessed September 19, 2025, https://www.orserdu.com/
65. Arvinas and Pfizer Announce FDA Acceptance of NDA for Vepdegestrant Following Positive Phase 3 VERITAC-2 Trial Results in Advanced Breast Cancer - Moomoo, accessed September 19, 2025, https://www.moomoo.com/news/post/56722322/arvinas-and-pfizer-announce-fda-acceptance-of-nda-for-vepdegestrant